Mebarek Heykel, Toumi Hind Farida, Nimeri Abdelrahmane
Director Center of General and Obesity Surgery of Algiers, Algiers, Algeria.
Head Department of Metabolic and Bariaric Surgery, Al Azhar Private Hospital, Algiers, Algeria.
Obes Surg. 2025 Aug 8. doi: 10.1007/s11695-025-08150-7.
One-Anastomosis Gastric Bypass (OAGB) has become an established bariatric procedure globally, known for its technical simplicity and favorable outcomes. Despite its increasing adoption, OAGB remains under scrutiny for long-term safety and efficacy.
This study aims to evaluate the clinical outcomes, safety, and resolution of obesity-related comorbidities following OAGB with a biliopancreatic limb (BPL) of 150 cm length, performed in a single center, over a three-year period.
This retrospective study included all patients who underwent laparoscopic OAGB between October 2020 and October 2023. The procedure was standardized with a BPL of 150 cm length. Data were collected and analyzed retrospectively to assess weight loss outcomes, resolution of comorbidities, and perioperative and late complications.
Overall, 102 patients underwent OAGB during the study period, with 76% being female and a mean age of 35.7 ± 8.34 years. The mean preoperative weight and body mass index (BMI) were 125 ± 16.2 kg and 46 ± 7.6 kg/m, respectively. The total weight loss (TWL) was 32,78 ± 5.57% at one year, 37,45 ± 4.36% at two years, and 37,85 ± 4.74% at three years. Significant improvements were noted in obesity-related comorbidities: 92% of patients with type 2 diabetes (T2D) experienced remission at one year, sustained at three years in 82%. Early complications were observed in 3.92% of cases, while late complications occurred in 7.84%, with no postoperative deaths or internal hernia reoperations during the three-year follow-up. Iron and ferritin deficiencies were identified in 4.9%, hypoalbuminemia (< 35 g/l) in 1.96%, and anemia (< 12 g/dl) in 4.9% of patients, with no patients requiring revision for malnutrition.
OAGB demonstrates high efficacy in achieving substantial weight loss and resolving comorbidities, with an acceptable safety profile when using a BPL of 150 cm. The findings support the continued adoption of OAGB as a primary bariatric surgery when performed with standardized techniques and multidisciplinary follow-up.
单吻合口胃旁路术（OAGB）已成为全球公认的减肥手术，以其技术简单和效果良好而闻名。尽管其应用越来越广泛，但OAGB的长期安全性和有效性仍受到审查。
本研究旨在评估在单一中心进行的、采用150厘米长胆胰支（BPL）的OAGB术后三年的临床结果、安全性以及肥胖相关合并症的缓解情况。
这项回顾性研究纳入了2020年10月至2023年10月期间接受腹腔镜OAGB手术的所有患者。手术采用标准化的150厘米长BPL。回顾性收集和分析数据，以评估体重减轻结果、合并症缓解情况以及围手术期和晚期并发症。
总体而言，在研究期间有102例患者接受了OAGB手术，其中76%为女性，平均年龄为35.7±8.34岁。术前平均体重和体重指数（BMI）分别为125±16.2千克和46±7.6千克/平方米。一年时的总体体重减轻（TWL）为32.78±5.57%，两年时为37.45±4.36%，三年时为37.85±4.74%。肥胖相关合并症有显著改善：92%的2型糖尿病（T2D）患者在一年时病情缓解，三年时仍有82%保持缓解。3.92%的病例出现早期并发症，7.84%出现晚期并发症，三年随访期间无术后死亡或内疝再次手术情况。4.9%的患者出现铁和铁蛋白缺乏，1.96%出现低白蛋白血症（<35克/升），4.9%出现贫血（<12克/分升），无患者因营养不良需要进行翻修手术。
OAGB在实现显著体重减轻和缓解合并症方面显示出高效性，使用150厘米长的BPL时安全性可接受。这些发现支持在采用标准化技术和多学科随访进行OAGB手术时，继续将其作为主要的减肥手术。
